Evaluation of WO2012003387, Gilead's ASK1 inhibitors.

A small number of novel N-(triazolylthiazol-2-yl) and N-(triazolylthienyl) benzamide and picolinamide derivatives are claimed. The compounds are ASK1 kinase inhibitors among which some have nanomolar potency and are potentially useful in the treatment of a diverse range of conditions. The claimed compounds define a pharmacophore, distinct from that described in the limited number of patent filings claiming ASK1 inhibitors.